Boston Scientific Buys Interventional Radiology Business

by | Nov 13, 2015 10:00 am | Medical Devices

The medical device sector just keeps plugging along with its mergers and acquisitions, with four announcements already in November. One was Boston Scientific Corporation (NYSE: BSX), which announced its acquisition of the interventional radiology business of CeloNova Biosciences, a global developer and manufacturer of endovascular and interventional cardiology technologies. The price was $70 million upfront, plus additional payments contingent on regulatory and sales milestones. BSX is taking on CeloNova’s Embozene Tandem Drug-Elutable Microspheres, which can be embedded with drugs used to treat liver cancer, and other oncology products. CeloNova has received an Investigational... Read More »

March Healthcare M&A Madness

by | Mar 30, 2015 2:37 pm | Biotechnology, Pharmaceuticals

March isn’t quite over as we write this, and neither is the madness—which won’t stop us from posting the biggest deals of the month. As of Friday, March 27, $34.4 billion has been committed to finance about 105 transactions. Of course, $21 billion of that comes from the AbbVie (NYSE: ABBV) acquisition of Pharmacyclics (NASDAQ: PCYC). Next week, preliminary Q1:15 results! Read More »

Year’s Biggest Billion-Dollar Deals Top $64 Billion

by | Mar 16, 2015 8:16 pm | Biotechnology, Pharmaceuticals

Already in 2015, we’ve recorded 11 billion-dollar-plus deals, for a total of $64.4 billion. Thanks to the $21 billion AbbVie (NYSE: ABBV) bid for Pharmacyclics (NASDAQ: PCYC), the biotechnology sector accounted for $27.5 billion of those big deals. Pharmaceuticals, with four billion-plus transactions, still ranks first, with combined spending of $30.45 billion.  Read More »